Two issues should be noted when designing a clinical trial to evaluate BCG effects on COVID-19
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-05-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1207212/full |
| _version_ | 1797822088496545792 |
|---|---|
| author | Wenping Gong Yinping Liu Yong Xue Li Zhuang Li Zhuang |
| author_facet | Wenping Gong Yinping Liu Yong Xue Li Zhuang Li Zhuang |
| author_sort | Wenping Gong |
| collection | DOAJ |
| first_indexed | 2024-03-13T10:02:42Z |
| format | Article |
| id | doaj.art-e9c425a98bfe45faa5dcec8df3729e45 |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-03-13T10:02:42Z |
| publishDate | 2023-05-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-e9c425a98bfe45faa5dcec8df3729e452023-05-23T04:36:59ZengFrontiers Media S.A.Frontiers in Immunology1664-32242023-05-011410.3389/fimmu.2023.12072121207212Two issues should be noted when designing a clinical trial to evaluate BCG effects on COVID-19Wenping Gong0Yinping Liu1Yong Xue2Li Zhuang3Li Zhuang4Beijing Key Laboratory of New Techniques of Tuberculosis Diagnosis and Treatment, Senior Department of Tuberculosis, The 8th Medical Center of PLA General Hospital, Beijing, ChinaBeijing Key Laboratory of New Techniques of Tuberculosis Diagnosis and Treatment, Senior Department of Tuberculosis, The 8th Medical Center of PLA General Hospital, Beijing, ChinaBeijing Key Laboratory of New Techniques of Tuberculosis Diagnosis and Treatment, Senior Department of Tuberculosis, The 8th Medical Center of PLA General Hospital, Beijing, ChinaBeijing Key Laboratory of New Techniques of Tuberculosis Diagnosis and Treatment, Senior Department of Tuberculosis, The 8th Medical Center of PLA General Hospital, Beijing, ChinaHebei North University, Zhangjiakou, Hebei, Chinahttps://www.frontiersin.org/articles/10.3389/fimmu.2023.1207212/fullBacillus Calmette-Guérin (BCG)tuberculosis (TB)COVID-19clinical triallatent tuberculosis infection (LTBI) |
| spellingShingle | Wenping Gong Yinping Liu Yong Xue Li Zhuang Li Zhuang Two issues should be noted when designing a clinical trial to evaluate BCG effects on COVID-19 Frontiers in Immunology Bacillus Calmette-Guérin (BCG) tuberculosis (TB) COVID-19 clinical trial latent tuberculosis infection (LTBI) |
| title | Two issues should be noted when designing a clinical trial to evaluate BCG effects on COVID-19 |
| title_full | Two issues should be noted when designing a clinical trial to evaluate BCG effects on COVID-19 |
| title_fullStr | Two issues should be noted when designing a clinical trial to evaluate BCG effects on COVID-19 |
| title_full_unstemmed | Two issues should be noted when designing a clinical trial to evaluate BCG effects on COVID-19 |
| title_short | Two issues should be noted when designing a clinical trial to evaluate BCG effects on COVID-19 |
| title_sort | two issues should be noted when designing a clinical trial to evaluate bcg effects on covid 19 |
| topic | Bacillus Calmette-Guérin (BCG) tuberculosis (TB) COVID-19 clinical trial latent tuberculosis infection (LTBI) |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1207212/full |
| work_keys_str_mv | AT wenpinggong twoissuesshouldbenotedwhendesigningaclinicaltrialtoevaluatebcgeffectsoncovid19 AT yinpingliu twoissuesshouldbenotedwhendesigningaclinicaltrialtoevaluatebcgeffectsoncovid19 AT yongxue twoissuesshouldbenotedwhendesigningaclinicaltrialtoevaluatebcgeffectsoncovid19 AT lizhuang twoissuesshouldbenotedwhendesigningaclinicaltrialtoevaluatebcgeffectsoncovid19 AT lizhuang twoissuesshouldbenotedwhendesigningaclinicaltrialtoevaluatebcgeffectsoncovid19 |